Table 1.
Summary of the main characteristics of the antibody-based interventions identified in the 31 original articles analyzed in this work.
| Target | Antibody | Clone | Epitope | References |
|---|---|---|---|---|
| mSOD1 | mAb | C4F6 | a.a. Asp90-Asp96 | Urushitani et al., 2007 |
| mMAb | D3H5 | D3H5: a.a. 24-55 | Gros-Louis et al., 2010 | |
| A5C3 | A5C3: a.a. 80-118 | |||
| Fab | D3H5 | |||
| HuMAb | HuMAb120c | HuMAb120c: a.a. 36-71 | Broering et al., 2013 | |
| HuMAb37L-63 | HuMAb37L-63: a.a. 11L-80 | |||
| mMAb | DSE2-3H1 | a.a. 125-142 | Pokrishevsky et al., 2017 | |
| hMAb | chα-mSOD1 | a.a. K76-V82 | Maier et al., 2018 | |
| scFv | D3H5 | a.a. 24-55 | Patel et al., 2014 | |
| SOD1 | mMAb | α-SOD1a143-153 | a.a. 143-153 | Lehmann et al., 2020 |
| α-SOD1 65-72 | a.a. 65-72 | |||
| scFv | B1 | Not specified | Ghadge et al., 2013 | |
| B12 | ||||
| scFv | B1 | Not specified | Ghadge et al., 2019 | |
| B12 | ||||
| scFv | W20 | Not specified | Dong et al., 2018 | |
| TDP-43 | mMAb | E6 | RRM1 domain | Pozzi et al., 2020 |
| scFv | 3B12A | a.a. D247 or the RRM2 | Tamaki et al., 2018 | |
| scFv | E652 | RRM1 domain | Pozzi et al., 2019 | |
| C9ORF72 repeats expansion | mMAb | 5F2 | Not specified | Zhou et al., 2017 |
| mMAb | 5F2 | Not specified | Khosravi et al., 2020 | |
| hAb | α-GA1, α-GP1, α-GA2 | Not specified | Nguyen et al., 2020 | |
| Nogo-A | HuMAb | Ozanezumab | N-Term of Nogo-A | Meininger et al., 2014 |
| HuMAb | Ozanezumab | N-Term of Nogo-A | Meininger et al., 2017 | |
| mMAb | GSK577548 | N-Term of Nogo-A | Bros-Facer et al., 2014 | |
| MuSK | hMAb | #13, #21, #22 | Not specified | Cantor et al., 2018 |
| Chimeric Ab | #13 | Not specified | Sengupta-Ghosh et al., 2019 | |
| IL-6R | HuAb | Tocilizumab | Not specified | Fiala et al., 2013 |
| HuAb | Tocilizumab | Not specified | Lam et al., 2016 | |
| NRP-1 | HuMAb | α-NRP1A | Sema3A docking CUB domains (a1a2) on NRP-1 | Venkova et al., 2014 |
| Myostatin | MAb | RK35 | Not specified | Holzbaur et al., 2006 |
| CD40L | MAb | MR1 | Not specified | Lincecum et al., 2010 |
| DR-6 | Mab | 5D10 | Not specified | Huang et al., 2013 |
| IFN-g | MAb | R4-6A2 | Not specified | Otsmane et al., 2014 |
| GD1a/GT1b | hAb | rHIgM12 | Not specified | Xu et al., 2015 |
| CTGF | hMAb | FG-3019 | Not specified | Gonzalez et al., 2018 |
| HMGB1 | HuMAb | 2G7 | a.a. 53-63 (box A of HMGB1) | Lee et al., 2019 |
a.a., amino acids; Ab, antibody; h, human; Hu, humanized; m, mouse; MAb, monoclonal antibody; mMAb, mouse monoclonal antibody; mSOD1, misfolded SOD1; scFv, single-chain variable fragment.